MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Price Stock Quantity  
USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MK-2206 2HCl Chemical Structure

MK-2206 2HCl Chemical Structure
Molecular Weight: 480.39

Validation & Quality Control

Cited by 178 publications:

18 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MK-2206 2HCl is available in the following compound libraries:

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Targets Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
IC50 8 nM 12 nM 65 nM
In vitro MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H292M3;sU2N6fG:2b4jpZ{BCe3OjeR?=MlryN{DPxE1?M4DmZVczKGh?MWrEUXNQNEj6VpJKdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=MlL6NlA2PzFyNkm=
A431M4LS[2tqdmG|ZTDBd5NigQ>?MWK1JO69VQ>?NHrue442KGh?MX\EUXNQMnqyV5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJsMnTTNlA2PzFyNkm=
HepG2MkjpR5l1d3SxeHnjJGF{e2G7NUH6boNqOTBizszNM3:1b|I1KGh?MWfEUXNQMX3T[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK=M{HuRVIyOjB3OUK1
Sk-Hep1M2XKR2N6fG:2b4jpZ{BCe3OjeR?=M{D6SFExKM7:TR?=NW[1[Yg5OjRiaB?=M{\WU2ROW09?NGHiOVBU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI>Ml3GNlEzODV7MkW=
OCUT1 cells harbored PIK3CA (H1047R+/+)NUDIXWNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rNdFMh|ryPM{DEV|Uh\A>?M4jUWGROW09?NUL5N2tLUUN3ME2wMlE1KM7:TR?=M33ST|IyOjh7Mk[3
K1 cells harbored PIK3CA (E542K+/+)NYTiWWRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrFN{DPxE1?MlPGOUBlNEnMRYFFVVORM3fod2lEPTB;MD61NkDPxE1?M{K5XVIyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+)NUD4cpJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\tO|Mh|ryPMV:1JIQ>NWH4W25UTE2VTx?=M13pbWlEPTB;MD6xPEDPxE1?NHG0dIEzOTJ6OUK2Oy=>
C643 cells harbored HRAS (G13R+/−)M2\xTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TNUlMh|ryPMoXqOUBlMm\wSG1UVw>?MUDJR|UxRTBwMkeg{txOMoOwNlEzQDl{Nke=
Hth7 cells harbored NRAS (Q61R+/−)NEDFTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm2O3hMOyEQvF2=MYW1JIQ>MXjEUXNQMX3JR|UxRTRwNTFOwG0>NGD3bG4zOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangementMmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTLN{DPxE1?NXzROmRsPSCmMVPEUXNQNIDvTGRKSzVyPUCuOVkh|ryPM1TaclIyOjh7Mk[3
Hth74NVL0b|NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLHN{DPxE1?MVy1JIQ>NE\COmlFVVORNGC0XWpKSzVyPUKuNVkh|ryPM{XPSlIyOjh7Mk[3
KAT18MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYiyfYg3OyEQvF2=MlHQOUBlNXnQbGxWTE2VTx?=NHHQbIlKSzVyPUSuOlIh|ryPNUX2Vpo3OjF{OEmyOlc>
SW1736M3rDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXRfGhrOTByIN88US=>NGe1dXI2KGR?MXHEUXNQNGnGRVdKSzVyPUS3MlU3KM7:TR?=NWS4fodTOjF{OEmyOlc>
WROMkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfKe3hiOTByMDFOwG0>MmeyOUBlMXnEUXNQNWOxbWVwUUN3ME6xNFAxKM7:TR?=NHrjbpEzOTJ6OUK2Oy=>
TAD2MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorqNVAxOCEQvF2=NYrTW3pWPSCmM1XadGROW09?NUjWfG0xUUN3ME6xNFAxKM7:TR?=Mnr0NlEzQDl{Nke=
LN229MWTBdI9xfG:|aYOgRZN{[Xl?M{nO[VAvPSEQvF2=MXW2NEBpMYDEUXNQMonERZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ?NE[2V3YzOjB3N{mxOC=>
T98GNIPaWGJCeG:ydH;zbZMhSXO|YYm=M2HYbFAvPSEQvF2=M1vlXFYxKGh?NGnVOG9FVVORMnLZRZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ?M3L1UlIzODV5OUG0
HC11M{DocWZ2dmO2aX;uJGF{e2G7MU[xNEDPxE1?NX2wRZo6OjRiaB?=NHPqWYNFVVORMVrJcohq[mm2czFOtk1k[XOnaX6gZY5lKEGGUmCgd5lvfGinc3nzMXmyNlQzPjZ{MR?=
MOLT-4M1njVWN6fG:2b4jpZ{BCe3OjeR?=M1fMbVExKM7:TR?=MV60PEBpNF7hZZJFVVORNFPicJdKSzVyPUGuO-KBkc7:TR?=M4Pt[lIzPjF2MkSz
CEM-RNEewV4VEgXSxdH;4bYMhSXO|YYm=NHHJeJYyOCEQvF2=NWDOVY9xPDhiaB?=MULEUXNQM4\zcGlEPTB;Mz6z5qCK|ryPMWOyNlYyPDJ2Mx?=
CEM-SNG[yNYJEgXSxdH;4bYMhSXO|YYm=MWGxNEDPxE1?M4LDUFQ5KGh?MlfvSG1UVw>?NGHhWWdKSzVyPUWuNgKBkc7:TR?=MoLINlI3OTR{NEO=
MOLT-4NGLmUoxHfW6ldHnvckBCe3OjeR?=MY[xNEDPxE1?NE\xZowzPCCqMUDEUXNQM3TLfGJtd2OtczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2Vib3[geIhmKGOnbHygZ5lkdGV?M3TZU|IzPjF2MkSz
MOLT-4M1LITWZ2dmO2aX;uJGF{e2G7NYSydZBzPOLCid88US=>NHzhdZY1KGh?MoTZSG1UVw>?MofoTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{PBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4VzM1u1TlIzPjF2MkSz
CEM-RMoL0SpVv[3Srb36gRZN{[Xl?NUHFPYxGPOLCid88US=>MYC0JIg>MnnNSG1UVw>?MlzWTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4VzM3T2W|IzPjF2MkSz
CEM-SM4nreGZ2dmO2aX;uJGF{e2G7MmTPOQKBkc7:TR?=M{G1Z|QhcA>?MkLVSG1UVw>?NWLkemVwUW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|VCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{MUWyNlYyPDJ2Mx?=
HepG2 cellMn32T4lv[XOnIFHzd4F6NUnnRmFkOjBizszNM4HLeVI1KGh?MV\EUXNQM2fmWWRwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?NUjuWoRUOjN5OUezNVk>
HepG2 cellMn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrGfZA{OCEQvF2=MXqyOEBpM3i2N2ROW09?M1\YVGlvcGmkaYTzJINmdGxiZ4Lve5RpMl25NlM4QTd|MUm=
HepG2 cellM2XCNmFxd3C2b4Ppd{BCe3OjeR?=NEGze2QzOCEQvF2=Mn3BNlQhcA>?M1fWO2ROW09?MVrJcoR2[2W|IHPlcIwh[XCxcITvd4l{M1PsZVI{Pzl5M{G5
GEOM{S0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\ZOVAxKG6PMnTEO|IhcA>?NYXE[5ZTTE2VTx?=MmfjTY5pcWKrdIOgZ4VtdCCpcn;3eIg>MoPRNlQ2QDF{M{G=
CNE-1NETDNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fnN|ExKM7:TR?=NVu5fmxlQTZiaB?=NEPIN29FVVORNXHiN|VLUUN3ME2yMlk3KM7:TR?=NUfJTnJVOjV|M{[5NlU>
CNE-2NVrpTWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LCVFExKM7:TR?=MmT2PVYhcA>?NHm2NXlFVVORNGXlR|lKSzVyPUSuOVMh|ryPNFHaTZYzPTN|NkmyOS=>
HONE-1NVXaVZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFG0NmEyOCEQvF2=M3zBeFk3KGh?NX2zTm0xTE2VTx?=MXvJR|UxRTNwM{eg{txONH3BPFMzPTN|NkmyOS=>
SUNE-1M3vLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\TNVAh|ryPNVjGWo15QTZiaB?=NWTMdpFNTE2VTx?=MWfJR|UxRTBwNUKg{txONEnLTpozPTN|NkmyOS=>
CNE-2NXG2Xmc{TnWwY4Tpc44hSXO|YYm=M{PwbFExKM7:TR?=MV[0PEBpNHHNcZBFVVORMlHwTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>?MnTINlU{OzZ7MkW=
HONE-1NY\SV4d3TnWwY4Tpc44hSXO|YYm=NEHSe4gyOCEQvF2=MmXYOFghcA>?MnfqSG1UVw>?MWjJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcyNV[3N4FSOjV|M{[5NlU>
NEC8M3HjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHZbFBKSzVyPUCuNFk3PTFizszNMYfTRW5ITVJ?
P12-ICHIKAWAMorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjIW3l3UUN3ME2wMlEyPjJizszNMnzPV2FPT0WU
MDA-MB-175-VIIMmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVr2SG9EUUN3ME2wMlE{PzN6IN88US=>MW\TRW5ITVJ?
AsPC-1NWW2V3pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzvOFk2UUN3ME2wMlIzOTJ{IN88US=>NYnDcm0xW0GQR1XS
T47DNGrpRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3aOWpKSzVyPUCuNlgzPSEQvF2=MlTCV2FPT0WU
HHMm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTBwM{CyPFMh|ryPNWHQO2FDW0GQR1XS
MOLT-16NUXLOWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;5[GlEPTB;MD6zNFMzKM7:TR?=NHrze|dUSU6JRWK=
ES5NEPmVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{OzUGlEPTB;MD6zOFQ2PSEQvF2=NHTCcZFUSU6JRWK=
RS4-11Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH[xeHlKSzVyPUCuN|Q3OSEQvF2=NXrweGo4W0GQR1XS
KARPAS-45MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjjSmo3UUN3ME2wMlM4OzJzIN88US=>MWnTRW5ITVJ?
NCI-H720MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\LbXFLUUN3ME2wMlM4Pjd7IN88US=>MYPTRW5ITVJ?
H9NYTPSZpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVn5V41vUUN3ME2wMlM5QDh|IN88US=>NFX5Z|VUSU6JRWK=
EFM-19NFTZcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwNESwNUDPxE1?M{O0TnNCVkeHUh?=
SBC-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTBwNESwN|Uh|ryPNFKyU5ZUSU6JRWK=
A4-FukNGLOfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TMT2lEPTB;MD60Olg3QCEQvF2=NIDtOFZUSU6JRWK=
NCI-H1563NV;IUIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTUNJo1UUN3ME2wMlQ5OTh7IN88US=>MmH3V2FPT0WU
HCC1419NUfR[IJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3ZTWM2OD1yLkS4PFkzKM7:TR?=NWH0XIFyW0GQR1XS
H-EMC-SSM2jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTBwNEm5N|kh|ryPM4f5NXNCVkeHUh?=
BHT-101M3:3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLlTWM2OD1yLkWyPVYyKM7:TR?=NX3oN3hiW0GQR1XS
IGROV-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHYTWM2OD1yLkW1NlQ6KM7:TR?=NF\WSYhUSU6JRWK=
HGC-27MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXXTWM2OD1yLkW2O|g{KM7:TR?=MlLTV2FPT0WU
MDA-MB-361M1rhRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3;z[mlEPTB;MD61O|c3OSEQvF2=NUK1PFZ4W0GQR1XS
KE-37MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUH1e3ZQUUN3ME2wMlU5OjZizszNM3rNTHNCVkeHUh?=
HCC70NFn6WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17LeGlEPTB;MD61PVgzPyEQvF2=MYTTRW5ITVJ?
LNCaP-Clone-FGCNF:0bnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjP[|RPUUN3ME2wMlYyODR6IN88US=>M3L6eHNCVkeHUh?=
HAL-01NFK1VIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrXdG1FUUN3ME2wMlYzOTNizszNMmPHV2FPT0WU
HTMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXOx[YhqUUN3ME2wMlY{OjN7IN88US=>M3e4ZXNCVkeHUh?=
MDA-MB-415NIPiO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLDVGQ4UUN3ME2wMlY{PjJ4IN88US=>MmSyV2FPT0WU
NOS-1NV7qeVVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PDbWlEPTB;MD62N|czOyEQvF2=M4fsWXNCVkeHUh?=
DU-145NWrhZ3JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV2yb|k{UUN3ME2wMlY1PzR3IN88US=>MlTWV2FPT0WU
OCUB-MMlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fpTWlEPTB;MD63NFk3PiEQvF2=NV;uOXRKW0GQR1XS
VA-ES-BJMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjpWXNKSzVyPUCuO|MxOjVizszNM{C2[nNCVkeHUh?=
J-RT3-T3-5MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTBwN{S0NFMh|ryPMYDTRW5ITVJ?
MOLT-4NInPSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rOUWlEPTB;MD64NFU5OiEQvF2=NYnqe4hUW0GQR1XS
NB7MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTseJJMUUN3ME2wMlgzPDFzIN88US=>NGrvNmRUSU6JRWK=
L-363M4nHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XJfWlEPTB;MD64N|Q1OiEQvF2=MnrDV2FPT0WU
NKM-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXXWYg{UUN3ME2wMlg3OjV|IN88US=>MXHTRW5ITVJ?
HOP-92MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjuTWM2OD1yLki3NlI{KM7:TR?=M1GxfHNCVkeHUh?=
OAW-42NWjhVpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXrSlN7UUN3ME2wMlg5PzJizszNNFzDWHhUSU6JRWK=
HuO9M1\3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7URpdtUUN3ME2wMlkzPzVzIN88US=>NVP3UFdMW0GQR1XS
MFE-280NG[1b|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvqUmVnUUN3ME2wMlk3PDZ3IN88US=>NH22bVZUSU6JRWK=
EM-2MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTCXXRKSzVyPUCuPVc6OzlizszNMUXTRW5ITVJ?
NCI-H520NVLtN41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXuXVZKSzVyPUCuPVg2QTJizszNMXTTRW5ITVJ?
LB2241-RCCMlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2O1cGlEPTB;MD65PVc{PCEQvF2=MWfTRW5ITVJ?
SK-NEP-1NFu1fXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGO3cnZKSzVyPUGuNVQ1QDVizszNM{jEe3NCVkeHUh?=
LXF-289NUHUVpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoOyTWM2OD1zLkG3NVU3KM7:TR?=NWPiSFk3W0GQR1XS
EPLC-272HNHyzVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\4TWM2OD1zLkG3NlU3KM7:TR?=NVjNT2t{W0GQR1XS
COLO-684M3:3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTFwMkO3NlUh|ryPNE\VN2JUSU6JRWK=
ES1MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vrRWlEPTB;MT6yOFA3PSEQvF2=MmnmV2FPT0WU
DOHH-2MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TQOGlEPTB;MT6yPFIxOyEQvF2=NGfXTYVUSU6JRWK=
CTB-1MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTFwMki5PUDPxE1?MVzTRW5ITVJ?
G-401MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HvRWlEPTB;MT6yPVc6PSEQvF2=NEnWTHVUSU6JRWK=
LoVoM{TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLyfohKUUN3ME2xMlMzPTN2IN88US=>M3\BU3NCVkeHUh?=
Ramos-2G6-4C10NFfxPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTMV5IxUUN3ME2xMlM{PzBzIN88US=>M4LmVHNCVkeHUh?=
MFM-223NUPMNmRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17JVmlEPTB;MT6zOFQ3OSEQvF2=NFXUfW5USU6JRWK=
PA-1NEjYS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTFwM{WyOlUh|ryPNIrTUmZUSU6JRWK=
697MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHuyeVZKSzVyPUGuN|c3OTZizszNMlrSV2FPT0WU
QIMR-WILMlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHMXW5mUUN3ME2xMlQ6OTF4IN88US=>M3zITXNCVkeHUh?=
HOSNULrPXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7PTWM2OD1zLkS5OVU5KM7:TR?=MVfTRW5ITVJ?
DMS-273MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\RcXpKSzVyPUGuOVE6PTlizszNNV7JWpU6W0GQR1XS
ME-180NGPLUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\pTWM2OD1zLkW2PFkyKM7:TR?=M3noZ3NCVkeHUh?=
HCC2218NE\weVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIT6ZnJKSzVyPUGuOlgzOjVizszNM2LHZ3NCVkeHUh?=
CAL-54MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTFwN{GyOFIh|ryPNGT3bXFUSU6JRWK=
OMC-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTFwN{S2O|ch|ryPNYGxUo9QW0GQR1XS
COR-L105NFz5R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHr5dZlKSzVyPUGuO|k4OzdizszNM3jadHNCVkeHUh?=
BV-173NYTKNXB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPjTWM2OD1zLkixNFc1KM7:TR?=MULTRW5ITVJ?
RKOM1Lqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fV[mlEPTB;MT64O|ExOSEQvF2=M2TZS3NCVkeHUh?=
SNU-387M3n5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXTUXpKSzVyPUGuPFg1ODZizszNNVLiU|dVW0GQR1XS
SW1088NHPqTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTFwOUS2NFYh|ryPM{XjUXNCVkeHUh?=
Hs-578-TNE\3fGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HaU2lEPTB;Mj6xNVQ{OyEQvF2=NVjHUXFNW0GQR1XS
OC-314MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jIS2lEPTB;Mj6xOVA5PiEQvF2=M1PDbnNCVkeHUh?=
RMG-INVzXRpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTJwMU[zPVgh|ryPNGS5bo5USU6JRWK=
NCI-H1395MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnLV5hEUUN3ME2yMlE5ODlzIN88US=>M2fQUnNCVkeHUh?=
GAMGM1\lU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi4b3BKSzVyPUKuNlM5PDVizszNM2nHfnNCVkeHUh?=
LB1047-RCCNWWzO4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHSxXJJKSzVyPUKuNlQ{OTdizszNNGnYfVFUSU6JRWK=
MN-60NFThe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTJwMkm5NlMh|ryPMmixV2FPT0WU
OAW-28MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17SXGlEPTB;Mj6yPVk2OSEQvF2=MljqV2FPT0WU
NCI-H2228Mo\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2L0NmlEPTB;Mj6zNVU2OiEQvF2=MlrFV2FPT0WU
ABC-1NHGyUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV23WWVXUUN3ME2yMlM{OjV|IN88US=>MWTTRW5ITVJ?
LS-513MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPRTWM2OD1{LkOzOFg1KM7:TR?=NGLpWXJUSU6JRWK=
KS-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLYTWM2OD1{LkO4NVkyKM7:TR?=MU\TRW5ITVJ?
NB69NYm3cnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIm5OoZKSzVyPUKuN|g6QDNizszNNXL6dXF[W0GQR1XS
VM-CUB-1NGnHRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PLZmlEPTB;Mj6zPVA5OyEQvF2=NGHM[plUSU6JRWK=
D-423MGNHfiUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfBb2ZSUUN3ME2yMlQyODR2IN88US=>NIDoeolUSU6JRWK=
EW-18M1rPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjjWIJ{UUN3ME2yMlQyQTN7IN88US=>MoPJV2FPT0WU
YH-13NUfZcWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJwNE[xOVMh|ryPNGnDS2ZUSU6JRWK=
T-24NEHRUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHftW2NKSzVyPUKuOFc5QDFizszNMn;5V2FPT0WU
ES8MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJwNEmyPFch|ryPNWrEZ5U2W0GQR1XS
ES3MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\4foNKSzVyPUKuOFk4PTlizszNMVPTRW5ITVJ?
RXF393M{nGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGL6c5ZKSzVyPUKuOlA1QDdizszNM3vxNHNCVkeHUh?=
RPMI-8226MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\WTWM2OD1{Lk[yPVU{KM7:TR?=NHT0bVNUSU6JRWK=
AGSNUSweVgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHVTWM2OD1{LkeyNVM4KM7:TR?=MmLWV2FPT0WU
HCC1395NEPjd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTJwN{WxPFch|ryPM37ufXNCVkeHUh?=
MV-4-11NHX1V3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPGTWM2OD1{Lke1NlY3KM7:TR?=M1OwZXNCVkeHUh?=
A204MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJwOEO4O|Ih|ryPMkTRV2FPT0WU
MCF7MmXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTJwOE[xNVch|ryPNYrON5AzW0GQR1XS
SNU-423MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJwOEmyOFIh|ryPNUXxd4JuW0GQR1XS
NCI-H1048MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfHTWM2OD1{Lkm2PFY2KM7:TR?=NH;OWVhUSU6JRWK=
GR-STNYPGSm06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDCfFhKSzVyPUOuNFQ3OTFizszNNX7QbYdOW0GQR1XS
EoL-1-NWTwUoh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:1e4NEUUN3ME2zMlA4ODV6IN88US=>NW\ufZltW0GQR1XS
HuH-7M132Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXoTWM2OD1|LkC5OFY1KM7:TR?=MX7TRW5ITVJ?
OS-RC-2NY\2[3dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\TPHVKSzVyPUOuNVEyQSEQvF2=MkfrV2FPT0WU
EW-3M3zlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmTwTWM2OD1|LkG5OVI6KM7:TR?=NVPLXo0{W0GQR1XS
NCI-H747NFTXWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLNfYlKSzVyPUOuNlA3QTRizszNNYPHe|h5W0GQR1XS
EW-16MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXC[YdUUUN3ME2zMlIyQDd7IN88US=>M{PCSHNCVkeHUh?=
DOKMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTNwMkK4OVkh|ryPNFzP[VBUSU6JRWK=
HCC2157MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPFeFZ{UUN3ME2zMlM5OTd7IN88US=>MoXYV2FPT0WU
OVCAR-3NYHpUWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLxflRKSzVyPUOuOFA4QDZizszNNHzuRYZUSU6JRWK=
NCI-H1623NV;ZcpdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XmWmlEPTB;Mz60NVIzPCEQvF2=NHWzS|VUSU6JRWK=
H4NHzKWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHWclg3UUN3ME2zMlQ2PjJ4IN88US=>NVrV[opwW0GQR1XS
SW1710M4PnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTNwNE[2O|gh|ryPMl7WV2FPT0WU
RT-112NWeweFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TMdGlEPTB;Mz61NlM5QCEQvF2=Mk\HV2FPT0WU
DMS-114NWPSc2t{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkWwTWM2OD1|Lk[yNlc5KM7:TR?=MmPLV2FPT0WU
AN3-CAMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\w[GlEPTB;Mz62NlQ2PiEQvF2=M{DWfHNCVkeHUh?=
KNS-62M{DMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmW3TWM2OD1|Lk[zN|M5KM7:TR?=NIqzeWVUSU6JRWK=
SJRH30MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTNwNkmxNlIh|ryPM3n2XXNCVkeHUh?=
G-402M1P1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvGTWM2OD1|LkewO|EyKM7:TR?=M2\TW3NCVkeHUh?=
MHH-PREB-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjNT5pKSzVyPUOuO|IxOzhizszNMVjTRW5ITVJ?
P30-OHKMoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITlc41KSzVyPUOuPFA6PzZizszNMX;TRW5ITVJ?
RVH-421NE\vO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3e3d2lEPTB;Mz64NVc5QCEQvF2=NUDmeVhTW0GQR1XS
LU-134-ANYXxdG1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PMXWlEPTB;Mz64PFQzQCEQvF2=MnnUV2FPT0WU
ECC10NIOyTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTNwOUO2NlIh|ryPM3fXWXNCVkeHUh?=
TGWMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjnbGhKSzVyPUSuNFI{ODVizszNMVfTRW5ITVJ?
MLMAM2TpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkSyTWM2OD12LkCyPVY3KM7:TR?=MUPTRW5ITVJ?
SCC-25MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUi5WlgzUUN3ME20MlA3PTZ4IN88US=>MWfTRW5ITVJ?
TYK-nuMmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;WSWNKSzVyPUSuNFk2OzRizszNM3m4VXNCVkeHUh?=
LAMA-84MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWH4Z|Z3UUN3ME20MlE1OTlzIN88US=>NGXobY1USU6JRWK=
Calu-3NVTmeoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXQfZRKSzVyPUSuNlQ1OTZizszNMXrTRW5ITVJ?
NCI-H460NULBZZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH1dYp[UUN3ME20MlI3PDR|IN88US=>Mn[1V2FPT0WU
EGI-1M3j4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rrXmlEPTB;ND6zO|c4QCEQvF2=NIP1[nRUSU6JRWK=
NCI-H292MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInGSFdKSzVyPUSuN|gyPDZizszNMoPiV2FPT0WU
HCE-TM3j3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jOc2lEPTB;ND60NVU4QSEQvF2=Mn7TV2FPT0WU
EW-11M4nZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3fjUWlEPTB;ND60NVg{QCEQvF2=MoTnV2FPT0WU
ATN-1NGjDfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnGUYltUUN3ME20MlQ1OzB2IN88US=>NWDWOlVjW0GQR1XS
NB5M1m0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTRwNUO2PVch|ryPMUXTRW5ITVJ?
KLEMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjYXmFKSzVyPUSuO|AyQThizszNNXLLW4h1W0GQR1XS
CAL-39MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTRwN{KxOFYh|ryPNWPyO3h3W0GQR1XS
TI-73MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnz5TWM2OD12LkiwOlA6KM7:TR?=NHHRdWVUSU6JRWK=
HO-1-N-1NYTVWYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTRwOUSyJO69VQ>?MlLSV2FPT0WU
786-0NGPMTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\zeWlEPTB;ND65OFY4OyEQvF2=NIjGRmRUSU6JRWK=
SK-N-DZMkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPFd2dKSzVyPUSuPVYyPDJizszNNVj6[FFiW0GQR1XS
NCI-H446MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTVwMkCwNFkh|ryPNFm5[VdUSU6JRWK=
ETK-1M3LhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDjN3dKSzVyPUWuNlEyPjVizszNM1XGUnNCVkeHUh?=
BT-20NGDydFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{C2WGlEPTB;NT6yNVM2OyEQvF2=NXmycmxPW0GQR1XS
MEL-HOMof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fZdGlEPTB;NT6zO|M{PiEQvF2=M4fqOHNCVkeHUh?=
CAL-27M3Wxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTVwNE[zN|kh|ryPNGq2SVZUSU6JRWK=
SW872MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nDPWlEPTB;NT61PVQzQCEQvF2=NGDEWXhUSU6JRWK=
RPMI-2650MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XpPGlEPTB;NT62OlE6QSEQvF2=M{DOSHNCVkeHUh?=
PFSK-1NEPRbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTVwN{K3N|Ih|ryPNV62XGFQW0GQR1XS
SF295NWXreZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4i4cGlEPTB;NT64NFY{OyEQvF2=MUPTRW5ITVJ?
BeckerMlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4j3VWlEPTB;NT64OlQ4OiEQvF2=MoP3V2FPT0WU
Saos-2NFHQTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;rT3dxUUN3ME21Mlg3PTNizszNM2jGS3NCVkeHUh?=
SK-OV-3MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml:0TWM2OD13Lkm5PFE3KM7:TR?=M{TVcXNCVkeHUh?=
VMRC-RCZNUPJR253T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LzRWlEPTB;Nj6wPFc4OyEQvF2=NU\xSnlbW0GQR1XS
EW-22MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4i3fWlEPTB;Nj6xPVY1QSEQvF2=NWO5XVREW0GQR1XS
BT-474M3jISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTaV4pKSzVyPU[uNlM{KM7:TR?=M36wRXNCVkeHUh?=
BFTC-909NWfnXFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDMSIZuUUN3ME22MlMxOzR3IN88US=>NH\zc4hUSU6JRWK=
NB12NVXOSmN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUiySmpUUUN3ME22MlM6ODdzIN88US=>NHH5OnNUSU6JRWK=
D-263MGM2jxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoSyTWM2OD14LkS1NVY6KM7:TR?=MXvTRW5ITVJ?
SNB75M1\lRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYW2NG9qUUN3ME22MlYxOTR|IN88US=>MmXaV2FPT0WU
A704NFX6OlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrWOY57UUN3ME22MlY{ODZizszNM1TL[XNCVkeHUh?=
NCI-H1693NYHNOpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\QTWM2OD14Lk[zOlA1KM7:TR?=NFjWW2VUSU6JRWK=
LN-405MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGryOGpKSzVyPU[uO|k3PzJizszNM1K1bHNCVkeHUh?=
CHL-1NVWweGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknpTWM2OD14LkiwNFc6KM7:TR?=NYTMWnJyW0GQR1XS
A498MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTZwOEG5OlEh|ryPNXXhT|RPW0GQR1XS
TE-12MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HUXWlEPTB;Nj64N|gyPyEQvF2=NELWdGFUSU6JRWK=
TE-6MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3yzSWlEPTB;Nj65N|A{QCEQvF2=M37BRXNCVkeHUh?=
AU565NHfnZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLpVWdKSzVyPU[uPVY6PTdizszNMoTyV2FPT0WU
RDMlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnBTWM2OD14Lkm4Nlg1KM7:TR?=MV\TRW5ITVJ?
SW1463M4PNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnm[G9KSzVyPUeuNVEyPjhizszNNVjPfm1qW0GQR1XS
LU-99ANYnVdIJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjPT3FKSzVyPUeuNVQ{OjJizszNMX;TRW5ITVJ?
NCI-H28MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTdwMkmyOEDPxE1?NVO5R|B6W0GQR1XS
MC-IXCMkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LwN2lEPTB;Nz60PFU4PiEQvF2=Mn:wV2FPT0WU
GP5dMn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWHsdVJ[UUN3ME23MlQ5PzZ2IN88US=>NUnzOGJFW0GQR1XS
GB-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTdwNUS4NFQh|ryPNGDmdHNUSU6JRWK=
CAL-33NX;yOIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rDSWlEPTB;Nz62OlI{OyEQvF2=NH\qSGlUSU6JRWK=
MSTO-211HMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3WwbmlEPTB;Nz62O|M{PiEQvF2=MmXlV2FPT0WU
TE-5M17hR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrFc5l{UUN3ME23Mlc6OzN2IN88US=>M3fVeXNCVkeHUh?=
D-566MGMojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIO2XldKSzVyPUiuNFQ1OjlizszNNVLPXWt[W0GQR1XS
JVM-3MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwMUWyOlgh|ryPMUTTRW5ITVJ?
T98GMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEH2cG1KSzVyPUiuNVgxPjdizszNNYnVO|IyW0GQR1XS
HCC1954NVvmTopIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL6dpBKSzVyPUiuOFUyODRizszNNUfqRm1oW0GQR1XS
SF126NWXXXlZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLrTWM2OD16LkS1PVM3KM7:TR?=M4rVUXNCVkeHUh?=
LB996-RCCMojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInyTo1KSzVyPUiuOVMzPTdizszNNEOxOWRUSU6JRWK=
SKG-IIIaM4PYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDXTWM2OD16Lk[zNFY6KM7:TR?=NHvaflNUSU6JRWK=
NCI-SNU-1NEC0RnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHX5bpFKSzVyPUiuOlQ3PDNizszNNYrDTGw1W0GQR1XS
LB771-HNCMo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRThwNkS2PVYh|ryPMl;3V2FPT0WU
SCC-4NVzZbpc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUX0ZpdNUUN3ME24MlY5OjF7IN88US=>MXzTRW5ITVJ?
CAMA-1MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XPdWlEPTB;OD63O|E1PiEQvF2=NXXnWZE3W0GQR1XS
D-502MGMn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzyXWtKSzVyPUiuO|g3OjlizszNM2S4dXNCVkeHUh?=
ESS-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnIcWRFUUN3ME24Mlg5PzB2IN88US=>MV7TRW5ITVJ?
HEC-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnVU45PUUN3ME24Mlg6QDZ4IN88US=>M3r6cHNCVkeHUh?=
NB10MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTlwMEKyNlQh|ryPMULTRW5ITVJ?
8505CMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnid2xKSzVyPUmuNFQzOzJizszNMnSwV2FPT0WU
EFO-27M{jmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\zTWM2OD17LkG2OFEzKM7:TR?=MkPPV2FPT0WU
HNM{nHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXKTWM2OD17LkG2OlI5KM7:TR?=NWf0eXg1W0GQR1XS
DSH1NV7ac2J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLUeIROUUN3ME25MlIxQDdizszNMUDTRW5ITVJ?
NBsusSRNY\hZm13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTqTWM2OD17LkK3OFAzKM7:TR?=NFvoc4RUSU6JRWK=
LS-123MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTlwM{G3OlEh|ryPMV7TRW5ITVJ?
SHP-77NFT4PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTlwM{m5N|Uh|ryPMX;TRW5ITVJ?
ACNNYmwdIdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnq2TWM2OD17LkWzNlc4KM7:TR?=NWWydIRmW0GQR1XS
U251NITKZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTlwNkW1OFQh|ryPM2ixcHNCVkeHUh?=
A431NEnaUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3q1T2lEPTB;OT64NFI{QCEQvF2=MoPUV2FPT0WU
5637Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\3RZlKSzVyPUmuPFQ6QDRizszNNYDofZVxW0GQR1XS
MDA-MB-157MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3mR4N[UUN3ME25MlkzQDd6IN88US=>M1;sTXNCVkeHUh?=
A101DNYq2fpV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\STWM2OD17Lkm5PVc1KM7:TR?=NVH3XZdrW0GQR1XS
YKG-1M1H5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTFyLkKwNFYh|ryPM1\iNXNCVkeHUh?=
LAN-6NWLocFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTFyLkKxOlQh|ryPM{DCV3NCVkeHUh?=
OVCAR-5M2XTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrSTWM2OD1zMD6yOFM{KM7:TR?=M{PFNXNCVkeHUh?=
A549Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nYbWlEPTB;MUCuN|k4OyEQvF2=MVvTRW5ITVJ?
no-11NFzybHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYD0XHJiUUN3ME2xNE41OzV|IN88US=>MUHTRW5ITVJ?
SF539NGjaUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2WzWGlEPTB;MUCuPVA1OSEQvF2=NVvocJVPW0GQR1XS
A388NVvGZpJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYC1SJhsUUN3ME2xNU4{QDl5IN88US=>NW[4dW1DW0GQR1XS
DELNELlXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlixTWM2OD1zMT60NlQh|ryPM37EUXNCVkeHUh?=
SW954NXS4VVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHP1cIdKSzVyPUGxMlQ3PjhizszNMWTTRW5ITVJ?
TK10NVzQeWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDCZVRvUUN3ME2xNU42OjdzIN88US=>Ml;NV2FPT0WU
SW756NYPaZW1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHXFTIJKSzVyPUGxMlUzQTRizszNM2DC[HNCVkeHUh?=
PC-3M{L0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHqTWM2OD1zMT61O|Y1KM7:TR?=NVqxeINHW0GQR1XS
ONS-76NH3PU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nWVGlEPTB;MUGuOlM3KM7:TR?=NVe3c4gzW0GQR1XS
A427MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFzLkewPVMh|ryPM3zqe3NCVkeHUh?=
MEG-01NYjQd2p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorZTWM2OD1zMT63OVA6KM7:TR?=Mo\JV2FPT0WU
BB30-HNCNYDDNWR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrDTWM2OD1zMT63PVgzKM7:TR?=MXvTRW5ITVJ?
NCI-H1299MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTFzLkiwPVMh|ryPNULYbotOW0GQR1XS
GCTM{jpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlO3TWM2OD1zMT64NlI5KM7:TR?=NVfrdnd[W0GQR1XS
D-247MGM3m3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3sR2NKSzVyPUGxMlk3PjNizszNNGDiVWtUSU6JRWK=
CFPAC-1NF;YWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\h[JRKSzVyPUGxMlk4QDJizszNMV3TRW5ITVJ?
EKVXNGDlNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH3fphKSzVyPUGyMlA{OTNizszNNFu4ZnBUSU6JRWK=
CAL-51MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjEVI9KUUN3ME2xNk4xPzF4IN88US=>M1v5enNCVkeHUh?=
BB49-HNCMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTJTWM2OD1zMj6xNVc4KM7:TR?=NHL4RlhUSU6JRWK=
RPMI-7951NHi5[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zufWlEPTB;MUKuNVg2PCEQvF2=MUnTRW5ITVJ?
RH-1NUTiOo1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTF{LkKxPFQh|ryPNWHRXodTW0GQR1XS
BCPAPNFjGOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTF{LkS3OFkh|ryPM3XWfXNCVkeHUh?=
GCIYNHLKbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\pRmlEPTB;MUKuOVIxQSEQvF2=M1\BZXNCVkeHUh?=
KNS-81-FDNEDMUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTF{LkW4Olkh|ryPM3jEeXNCVkeHUh?=
KYSE-140MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUC1N5IyUUN3ME2xNk45PTl3IN88US=>M{PnTXNCVkeHUh?=
Ca-SkiMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXRTWM2OD1zMj65NFQyKM7:TR?=MlL1V2FPT0WU
TGBC1TKBNGfufm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYH0ZYJXUUN3ME2xNk46OTF3IN88US=>NVXxO3JwW0GQR1XS
HCC1187MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTF|LkG5NVIh|ryPNH;MZWpUSU6JRWK=
SJSA-1NVLONWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV:1WGZzUUN3ME2xN{4zOzJ5IN88US=>MX7TRW5ITVJ?
CTV-1NHHr[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2S1eWlEPTB;MUOuN|Q2KM7:TR?=MoOyV2FPT0WU
WM-115NVH1S5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHBe3JKSzVyPUGzMlY1QDNizszNNITxRmdUSU6JRWK=
CHP-212NFj0U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHSTGtKSzVyPUGzMlk4OzlizszNNWXOc5N6W0GQR1XS
SCC-15MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYf6S45xUUN3ME2xN{46Pzd3IN88US=>NV3j[ZNvW0GQR1XS
BPH-1M1TWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjLTWM2OD1zND6xOlY1KM7:TR?=MYHTRW5ITVJ?
SW780MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXS4fYFQUUN3ME2xOE42ODJ3IN88US=>Mn7DV2FPT0WU
NCI-H2291MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LwSWlEPTB;MUSuOVg4QCEQvF2=MmLBV2FPT0WU
JEG-3NImxcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlG0TWM2OD1zND62N|I3KM7:TR?=MkGyV2FPT0WU
CAL-120NVXJU5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPqTWM2OD1zND63NFI4KM7:TR?=Ml3wV2FPT0WU
NCI-H23MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33ye2lEPTB;MUSuO|k6PyEQvF2=NH3xO4xUSU6JRWK=
MS-1NVzKO3RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIi0cYFKSzVyPUG0Mlk3OTFizszNM2\5VXNCVkeHUh?=
PC-14NWn5OpRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnizTWM2OD1zND65OlU1KM7:TR?=NGjm[ZlUSU6JRWK=
D-283MEDNFXze3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTF3LkCxNVEh|ryPM2LWWHNCVkeHUh?=
OE19MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHj3S2VKSzVyPUG1MlE2PDFizszNM2HU[nNCVkeHUh?=
CAS-1MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2C0PWlEPTB;MUWuOFE5PCEQvF2=MXzTRW5ITVJ?
NCI-H727MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHnTWM2OD1zNT60NlIyKM7:TR?=NWe3WFlxW0GQR1XS
SiHaMkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnGb41VUUN3ME2xOU44PTl2IN88US=>MXnTRW5ITVJ?
BFTC-905MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rIN2lEPTB;MUWuO|Y6PCEQvF2=MmHTV2FPT0WU
MDA-MB-453M1;PXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXlNXBsUUN3ME2xOk4yPjR{IN88US=>M{HaVHNCVkeHUh?=
HuP-T3MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFn4NZVKSzVyPUG2MlY{PzNizszNM3H2[3NCVkeHUh?=
SK-LU-1NEPiWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGixSHlKSzVyPUG2MlY6PTZizszNMofvV2FPT0WU
Detroit562NFzWNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;uTWM2OD1zNj63N|E5KM7:TR?=NIHvfINUSU6JRWK=
HCC1569NEnq[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXaOGozUUN3ME2xOk45OzN5IN88US=>NFHkUFZUSU6JRWK=
SK-MES-1MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTF4Lki0NVkh|ryPNVPpWnk{W0GQR1XS
BB65-RCCM2HSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFuzNXFKSzVyPUG3MlA1PzlizszNNWXZcnI5W0GQR1XS
LOXIMVIM1PqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XZb2lEPTB;MUeuNFcxPyEQvF2=MorTV2FPT0WU
SW1783NX30SZVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Czb2lEPTB;MUeuNVI5KM7:TR?=NGXsSVFUSU6JRWK=
NH-12NFvjTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknUTWM2OD1zNz6zN|A{KM7:TR?=MkXaV2FPT0WU
UACC-257NYnzW|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTF5LkW1NVIh|ryPNWXkeY9rW0GQR1XS
KOSC-2NIjGfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVfSfZd1UUN3ME2xO{43PzV5IN88US=>NWPBWmhYW0GQR1XS
KG-1MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfiRYVKSzVyPUG3MlY6OzdizszNM4j2NnNCVkeHUh?=
M059JNEXFOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUG4U2lvUUN3ME2xO{44ODNizszNM3\kUnNCVkeHUh?=
MHH-NB-11MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHYelRiUUN3ME2xO{46Pjd|IN88US=>MXvTRW5ITVJ?
EW-1M2C4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDGTWM2OD1zOD6xN|gzKM7:TR?=NG\4Z5ZUSU6JRWK=
CAL-85-1M1TsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTF6LkKzOVch|ryPNVO1PIxsW0GQR1XS
639-VM2DtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTF6LkOzOVQh|ryPNFziT4xUSU6JRWK=
C32M3Pwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnS[5Q4UUN3ME2xPE41PzJ5IN88US=>NFjX[VNUSU6JRWK=
KM-H2M1nsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPjTWM2OD1zOD61NlMzKM7:TR?=M{Txe3NCVkeHUh?=
A253MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXQc414UUN3ME2xPE44Ojh4IN88US=>MoTxV2FPT0WU
NCI-N87NFrUdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHrVFhKSzVyPUG4MlkxODhizszNM1;Oe3NCVkeHUh?=
8-MG-BANITCdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTF7LkC2OFYh|ryPM4DrdHNCVkeHUh?=
GI-ME-NM2qzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYWyW|NCUUN3ME2xPU4yPTR4IN88US=>NFj2eVlUSU6JRWK=
8305CNWLiZol6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTF7LkKyPFYh|ryPNFq5TW1USU6JRWK=
TE-8NGrUcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnGT2VKSzVyPUG5MlMxOjRizszNMonNV2FPT0WU
KYSE-270NIH3[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjTTWM2OD1{MD6wNlE4KM7:TR?=NYWzbo0yW0GQR1XS
HL-60MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;RVZNKSzVyPUKwMlA6PDFizszNNWXTSHdEW0GQR1XS
Mo-TMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTJyLkG2OlUh|ryPM{TQW3NCVkeHUh?=
NCI-H1355NFTERnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[2TWM2OD1{MD6zN|c1KM7:TR?=NGr4S2hUSU6JRWK=
HT-1080NIHZTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\pTWM2OD1{MD61OFk4KM7:TR?=MkjiV2FPT0WU
MIA-PaCa-2MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTJyLk[4PFMh|ryPMWLTRW5ITVJ?
NCI-H441MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\xSXlQUUN3ME2yNE44Ozd7IN88US=>MXTTRW5ITVJ?
LCLC-97TM1MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDzTXNKSzVyPUKwMlgyOzRizszNM3LsU3NCVkeHUh?=
HT-3MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3Qc2JKSzVyPUKxMlU3OzFizszNNFjnbmZUSU6JRWK=
22RV1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHL[JlwUUN3ME2yNU42Pjh3IN88US=>NX:zRY9{W0GQR1XS
LK-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nIcWlEPTB;MkGuOVk2OyEQvF2=MWLTRW5ITVJ?
CW-2MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rEeGlEPTB;MkGuOlA3QSEQvF2=NWG4PWo{W0GQR1XS
KYSE-510Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TxU2lEPTB;MkGuOlA6PSEQvF2=MorLV2FPT0WU
CGTH-W-1NWjYTppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJzLkexOlYh|ryPM1foeHNCVkeHUh?=
NCI-H661MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTJ{LkCzOEDPxE1?NGH0PYtUSU6JRWK=
KU-19-19NHPBfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7yRWtKSzVyPUKyMlE3QTdizszNM3PKRXNCVkeHUh?=
NCI-H2122NGWyb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;5[oZKSzVyPUKyMlI1OzJizszNM2LXXnNCVkeHUh?=
NCI-H526Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJ{LkO4PVUh|ryPMYjTRW5ITVJ?
NCI-H1650M4rYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIi2VoxKSzVyPUKyMlc3PCEQvF2=NGD1eYdUSU6JRWK=
AM-38M4frd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnqzTWM2OD1{Mj64Olg6KM7:TR?=M1G0enNCVkeHUh?=
NCI-H2405NFjObFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTJ|LkK1N|Mh|ryPM2\WfHNCVkeHUh?=
M14NUi4[483T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjNd3lKSzVyPUKzMlQxQDhizszNNUTKdnl2W0GQR1XS
ES4M4OxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvkXYxuUUN3ME2yN{41OjN{IN88US=>NIXpfXRUSU6JRWK=
DJM-1M2n0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XWV2lEPTB;MkOuOVI{PCEQvF2=MWDTRW5ITVJ?
S-117MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlK2TWM2OD1{Mz63OlUyKM7:TR?=MVHTRW5ITVJ?
MZ2-MELM2XxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF2yfINKSzVyPUKzMlc4PTlizszNMYTTRW5ITVJ?
SK-MEL-2MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFj6ZphKSzVyPUKzMlgyOzNizszNMn7hV2FPT0WU
HCC1806NEjBRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXCcmVKSzVyPUKzMlg4ODlizszNM2\Pc3NCVkeHUh?=
NMC-G1NHrWUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXCTWM2OD1{ND6yNlI3KM7:TR?=NVj4XohCW0GQR1XS
DK-MGNILyXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkC2TWM2OD1{ND6yPVQh|ryPM{HPN3NCVkeHUh?=
SK-N-FIMoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnn3TWM2OD1{ND6zN|AzKM7:TR?=MmDGV2FPT0WU
KINGS-1NHHGXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrwO5NKSzVyPUK0MlQ5PzRizszNNH\p[21USU6JRWK=
HCC2998M2HtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJ2LkS4PFUh|ryPMVTTRW5ITVJ?
ALL-POMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HLOmlEPTB;MkSuOlE6KM7:TR?=MYnTRW5ITVJ?
MPP-89NH7HNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrOTWM2OD1{NT6wOFU5KM7:TR?=NEHFSlBUSU6JRWK=
NCI-H2342M2HDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrUeHE1UUN3ME2yOU4yQTV|IN88US=>M2XyPXNCVkeHUh?=
TE-1NXzRbYs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUT4ZmdtUUN3ME2yOU4{PTZ|IN88US=>M3rJSXNCVkeHUh?=
RH-18MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fyW2lEPTB;MkWuOVkyQCEQvF2=NEf5O4VUSU6JRWK=
HT-1376M3joSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULoTJpKUUN3ME2yOU43PDZ3IN88US=>NW\XXmRxW0GQR1XS
U-2-OSMmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfpdoxKSzVyPUK1MlY5QDhizszNMmDwV2FPT0WU
BT-549MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojiTWM2OD1{NT65NFEyKM7:TR?=NFz3XIxUSU6JRWK=
NCI-H1755M3\CbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;LSpVKSzVyPUK1Mlk6PDVizszNNGrGTo5USU6JRWK=
EW-13MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\1TWM2OD1{Nj6wNlc1KM7:TR?=NWD6ZotMW0GQR1XS
NB13M4TaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{O4TmlEPTB;Mk[uNFk1QSEQvF2=NITaeVhUSU6JRWK=
NUGC-3M{jJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\LRYFKSzVyPUK2MlIyODNizszNMl;UV2FPT0WU
GMS-10MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXYTWM2OD1{Nj6yN|U{KM7:TR?=MoH6V2FPT0WU
CHP-134NVzKTXlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3ITWM2OD1{Nj6zPFY4KM7:TR?=NVfBTZFLW0GQR1XS
SW962M1nJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJ4LkWwNlEh|ryPNULVOpQ1W0GQR1XS
SNU-449M3;rWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXVTWM2OD1{Nz6wPFA{KM7:TR?=M4[yNHNCVkeHUh?=
HuP-T4NU\sOFFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTYWmh6UUN3ME2yO{4xQDd7IN88US=>M1rnVHNCVkeHUh?=
SW948M4f4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPhTWM2OD1{Nz6xN|Q1KM7:TR?=Mn;EV2FPT0WU
NCI-H226NWnRUnVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3neGlDUUN3ME2yO{41PTd6IN88US=>MXHTRW5ITVJ?
SK-PN-DWNIjROWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\H[4ZWUUN3ME2yO{43ODF{IN88US=>NFX1S|dUSU6JRWK=
GI-1MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDJdnlrUUN3ME2yO{44OjFizszNMmHSV2FPT0WU
CAL-12TM1jyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\PXHdKSzVyPUK4MlEyOTJizszNMoj6V2FPT0WU
YAPCNG\zO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnTZ3hNUUN3ME2yPE4zPTZ2IN88US=>M3;hZ3NCVkeHUh?=
SNU-C2BMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;uNXhKSzVyPUK4MlI6PjRizszNNXX0SnZsW0GQR1XS
RCC10RGBMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTJ6LkW0NVch|ryPMm[3V2FPT0WU
ES7M{PMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17iXmlEPTB;MkmuNVQ3PSEQvF2=MmDwV2FPT0WU
PANC-03-27NVLTbXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHO0V2FKSzVyPUK5MlQ1PCEQvF2=MlXYV2FPT0WU
ES6Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYn2VWxyUUN3ME2yPU45OTV5IN88US=>MlrmV2FPT0WU
HT-1197NHXRN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTNyLkC1PVgh|ryPMlvrV2FPT0WU
ZR-75-30MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TPNWlEPTB;M{CuNlM5OyEQvF2=MnrUV2FPT0WU
DBNVTxeHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzSTWM2OD1|MD60PVQzKM7:TR?=M1\jSnNCVkeHUh?=
OCI-AML2M3f4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUiy[HloUUN3ME2zNU4xPjlizszNNVHHNo44W0GQR1XS
NCI-H2170MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3:1VmlEPTB;M{GuPFUyPiEQvF2=MUnTRW5ITVJ?
IST-MES1M2TLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XXUGlEPTB;M{KuNlg6PyEQvF2=MlToV2FPT0WU
769-PNVj6NJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PC[GlEPTB;M{KuN|Y1OSEQvF2=NUT1THNoW0GQR1XS
COR-L23NUH5[VhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXZSGhwUUN3ME2zNk46ODd|IN88US=>MUHTRW5ITVJ?
SW626M{[3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLtcoNKSzVyPUOzMlE4PzZizszNM1;aZnNCVkeHUh?=
LU-139NEH1ZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInCNVlKSzVyPUOzMlY3ODVizszNMX7TRW5ITVJ?
HT-144NEHmdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLHVHFKSzVyPUOzMlg3OyEQvF2=NH\MTodUSU6JRWK=
CaR-1M4nqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;lTWM2OD1|Mz65PFIzKM7:TR?=NX72WGkyW0GQR1XS
OE33M17zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTN2LkK4OVUh|ryPMULTRW5ITVJ?
COLO-800NHvHW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn[5TWM2OD1|ND6zOlQ4KM7:TR?=MVnTRW5ITVJ?
NB14M3PofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFL2NIRKSzVyPUO0MlQ3QDRizszNNWrwOJRMW0GQR1XS
KURAMOCHIMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPxe3ZKSzVyPUO2MlEyQThizszNM3TLWHNCVkeHUh?=
SW48MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDjWYFKSzVyPUO2MlI1PzRizszNMWLTRW5ITVJ?
DaoyNXrGO4tZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHz6U3NKSzVyPUO2MlY2OzhizszNMm\RV2FPT0WU
TGBC24TKBNUDxeY9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzxTWM2OD1|Nj62O{DPxE1?M3i2eHNCVkeHUh?=
DU-4475NEHRfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjUTWM2OD1|Nj65NFM{KM7:TR?=MkPXV2FPT0WU
SW1417NFX3bIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PhUWlEPTB;M{iuNFU2OiEQvF2=NGr0WIpUSU6JRWK=
EFO-21NV\SWoRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLIb5dKSzVyPUO4Mlk{PDlizszNM2\SZXNCVkeHUh?=
MG-63NIj3SFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1f5fWlEPTB;M{muN|QzPCEQvF2=MULTRW5ITVJ?
LC-2-adNH7RS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITMfplKSzVyPUO5MlU2OTJizszNNH7rfZVUSU6JRWK=
NOMO-1M{fDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTN7LkiyO|Qh|ryPMoLYV2FPT0WU
COLO-741M4\VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LiT2lEPTB;NECuNVMxPCEQvF2=NYjkXFE{W0GQR1XS
BxPC-3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DkOWlEPTB;NECuOVY5PiEQvF2=NFHRVIJUSU6JRWK=
HSC-2NYK3UFR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrwfWl[UUN3ME20NE46OTF|IN88US=>MnfxV2FPT0WU
UMC-11M{LNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS0TWM2OD12MT6yOlMh|ryPM2XaXHNCVkeHUh?=
HCC1937Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjuTWM2OD12Mj63PFQ{KM7:TR?=NYWwflU3W0GQR1XS
Calu-6NW\INW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTR|LkKzPFIh|ryPNFT2VYNUSU6JRWK=
NCI-H1573Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHVb3E6UUN3ME20N{4{PDd5IN88US=>NUPFOoFtW0GQR1XS
SK-N-ASMoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYq0NopnUUN3ME20N{43ODF7IN88US=>MULTRW5ITVJ?
PSN1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vEd2lEPTB;NEWuNlU1QCEQvF2=NIXUPHhUSU6JRWK=
TE-11NF60SJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXOTWM2OD12NT60PFQzKM7:TR?=MVPTRW5ITVJ?
NCI-H1155M3;aRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zsR2lEPTB;NEWuPFk3PyEQvF2=M1nn[XNCVkeHUh?=
KM12M1yyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\4NIxKSzVyPUS1MlkxPzZizszNM2Lr[XNCVkeHUh?=
RO82-W-1NYnsXpl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvMTWM2OD12Nj65PFIzKM7:TR?=NYnvS3k3W0GQR1XS
SW1573NWnnelJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlX4TWM2OD12Nz6zO|M3KM7:TR?=NIDZZY5USU6JRWK=
CAKI-1MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4GyVmlEPTB;NEiuNlg1PSEQvF2=Ml;xV2FPT0WU
U-118-MGMl2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DpTmlEPTB;NEiuN|cxOiEQvF2=NUe5dVVFW0GQR1XS
KYSE-520MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDYZVJKSzVyPUS4MlQxOTZizszNMWHTRW5ITVJ?
HT55MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\uTWM2OD12OT6xOFc1KM7:TR?=MnS3V2FPT0WU
ChaGo-K-1MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTR7LkS3PVMh|ryPNV[3emhiW0GQR1XS
IA-LMMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TBNWlEPTB;NUSuOlMzOiEQvF2=M2flUnNCVkeHUh?=
UACC-62MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoL2TWM2OD13NT6xNFQ3KM7:TR?=M2XKcXNCVkeHUh?=
MKN7NF3Me2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;rbVVKSzVyPUW2MlAzQDVizszNNUjEfJFxW0GQR1XS
HPAF-IINWHnUJpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUW4UIhDUUN3ME21Ok41ODd|IN88US=>MoftV2FPT0WU
NTERA-S-cl-D1MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTV5Lke3PEDPxE1?NXLlfVJPW0GQR1XS
FTC-133MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIT4ZpZKSzVyPUW4MlA6PjlizszNMmKyV2FPT0WU
MHH-ES-1NHTITINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3[yUWlEPTB;NUiuOFgyPCEQvF2=NYTHTmhbW0GQR1XS
JVM-2M4XCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TGXWlEPTB;NUiuPVUxPiEQvF2=Mmr3V2FPT0WU
TCCSUPM3\2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTRTWM2OD13OT61Nlc6KM7:TR?=M4\oe3NCVkeHUh?=
COLO-824M4L1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13zdGlEPTB;NkCuNFcyQSEQvF2=NWnF[Yt4W0GQR1XS
647-VNILlRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF33THBKSzVyPU[wMlE{PDdizszNMkHPV2FPT0WU
HD-MY-ZNGryfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnONXdwUUN3ME22NE42Ojl2IN88US=>NWK2c2FOW0GQR1XS
LS-411NNY[yU4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTZzLkO5NFMh|ryPMY\TRW5ITVJ?
NCI-H596NIPBZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\MTWM2OD14Mj63OFk3KM7:TR?=MojyV2FPT0WU
C-33-ANYftdZVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XDUGlEPTB;NkSuNFk2PyEQvF2=NGT5UINUSU6JRWK=
BHYNU[wdo56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT6T5d1UUN3ME22OE4yOjR3IN88US=>NGf1V|VUSU6JRWK=
KGNM1S5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vMdmlEPTB;NkSuOVUyPCEQvF2=NGnw[oxUSU6JRWK=
NCI-H1092MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTZ3LkCwPVUh|ryPNXnMXpNtW0GQR1XS
MZ1-PCMknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTZ3LkW2OFkh|ryPNY\nNm4zW0GQR1XS
LB831-BLCNXXJeWgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nGcGlEPTB;NkWuPFQ5OSEQvF2=MkP6V2FPT0WU
SW620NVHNNlFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXITWM2OD14Nj6yNFM6KM7:TR?=M2naSnNCVkeHUh?=
HuO-3N1NIPKcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPqSY9KSzVyPU[4MlMzOzhizszNNUnPXVNbW0GQR1XS
SK-HEP-1NV[wbGw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDQTWM2OD14OT65OFg3KM7:TR?=M{G3VHNCVkeHUh?=
LCLC-103HNH\6UIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHSwflVKSzVyPUewMlY4ODVizszNMX;TRW5ITVJ?
KYSE-70NVThfZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTdyLke4N|Uh|ryPNXq2e4pGW0GQR1XS
MewoNIPGVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fpV2lEPTB;N{GuOVA2KM7:TR?=NFTBcI1USU6JRWK=
COLO-668NEi5c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXhWG9KSzVyPUexMlg1PTFizszNNFq4PYtUSU6JRWK=
NCI-H522NYn5ZWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfzSlNrUUN3ME23Nk4{PDF|IN88US=>NXP3foFNW0GQR1XS
NCI-H1437M3TPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDHTWM2OD15ND60NFQ5KM7:TR?=M3:3dHNCVkeHUh?=
U-266MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjV[YdKSzVyPUe1MlQ2OTZizszNNHvwSnJUSU6JRWK=
MC116Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILPVJJKSzVyPUe1MlU4ODhizszNNGHhU3pUSU6JRWK=
PANC-10-05NFTBU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLHUmJKSzVyPUe3MlQzPDNizszNM{LGTXNCVkeHUh?=
KYSE-180NVLTRZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1KyT2lEPTB;N{euOVQ2PCEQvF2=MUfTRW5ITVJ?
JARMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHYU|NzUUN3ME23PU4xPTR4IN88US=>NUTRU2NiW0GQR1XS
CAL-62Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTTTWM2OD16MD6wPVUh|ryPMmf2V2FPT0WU
A3-KAWNE\nRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHH6cpdKSzVyPUiwMlIyPTRizszNMXrTRW5ITVJ?
PANC-08-13MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfwV4FxUUN3ME24NU4yPzZ6IN88US=>Mmn1V2FPT0WU
HSC-3NEDzNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{T1SWlEPTB;OEOuN|A4OSEQvF2=NUnBcm1YW0GQR1XS
HTC-C3M133NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTh|LkS3NFIh|ryPNGXiPHpUSU6JRWK=
KY821NIHFZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnGyTWM2OD16ND6wPFkzKM7:TR?=NHXWNm9USU6JRWK=
DoTc2-4510MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nkRmlEPTB;OESuNlE5PSEQvF2=NVqzXJNyW0GQR1XS
NCI-H1581MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moq2TWM2OD16NT60OlQyKM7:TR?=M{ixbXNCVkeHUh?=
KARPAS-299Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPaTWM2OD16Nj6xPVc4KM7:TR?=NXjUO|B6W0GQR1XS
IST-MEL1MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTjTWM2OD16Nj64PFczKM7:TR?=MWjTRW5ITVJ?
KP-N-YSNGO3d3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\jZXZ{UUN3ME24PU46ODJ6IN88US=>NFq3[HNUSU6JRWK=
KYSE-410M3LjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrVN2lYUUN3ME25NU41ODR{IN88US=>NX3aXXA{W0GQR1XS
TE-10NVy1NnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfPbVBoUUN3ME25NU42PjFzIN88US=>NVLOVo9FW0GQR1XS
SK-MEL-1MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mme5TWM2OD17Mj65NVA3KM7:TR?=M2e5eXNCVkeHUh?=
COLO-792MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYi1bppoUUN3ME25OU4zPTZ2IN88US=>MXrTRW5ITVJ?
SCHM3TOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHpTWM2OD17Nj6zPFc4KM7:TR?=NX7LW3NIW0GQR1XS
NCI-H1792NFPvd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXns[mN6UUN3ME25Ok45QTl{IN88US=>NVjHWWZkW0GQR1XS
NCI-H2029MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTod5M4UUN3ME25Ok46PTZ4IN88US=>NEnVeVlUSU6JRWK=
SW684MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFS4[HNKSzVyPUm4MlY3PTRizszNM3HMUXNCVkeHUh?=
NCI-H209M36zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXQTWM2OD1zMECuNVIyKM7:TR?=NEnj[GRUSU6JRWK=
HLEM{\kdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTFyNT6yPFIh|ryPMYfTRW5ITVJ?
GOTONIrtV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDsbYRKSzVyPUGwO{44PzdizszNNGHldFJUSU6JRWK=
NCI-H1793NHXCWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jIUmlEPTB;MUC5MlI5KM7:TR?=M1jyNnNCVkeHUh?=
D-392MGNV;y[4F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DDVWlEPTB;MUG3MlM6QCEQvF2=NWXyR25LW0GQR1XS
SW1990Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXSeGZ[UUN3ME2xNlAvQTVzIN88US=>NWTafJVXW0GQR1XS
ML-2MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTkOnhKSzVyPUGyNU43PzZizszNMXvTRW5ITVJ?
NCI-H2452MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1O0UmlEPTB;MUKyMlIyKM7:TR?=MmXJV2FPT0WU
SK-MEL-30M1vuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLa[4tuUUN3ME2xNlMvOjR2IN88US=>NFvjUGJUSU6JRWK=
SN12CMl;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnSxTWM2OD1zMkSuNVc3KM7:TR?=NEDUNWhUSU6JRWK=
NCI-H1770NY\Kc45pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\uTYtrUUN3ME2xNlUvPTF2IN88US=>MWLTRW5ITVJ?
SF268NXTuPZd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXaVZRKSzVyPUGyOk4yPThizszNNV[zRoo{W0GQR1XS
BALL-1M13WSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLiTWM2OD1zMk[uNlMh|ryPMk\NV2FPT0WU
COLO-679M1K1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknWTWM2OD1zMk[uO|U{KM7:TR?=NWfMSWNlW0GQR1XS
A2780MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnUbZFVUUN3ME2xNlgvQTh6IN88US=>NXnrNZRIW0GQR1XS
NCI-H1651M3\KW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2X2fmlEPTB;MUOxMlI1OyEQvF2=Mne3V2FPT0WU
NCI-H2087NGHPW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvHTWM2OD1zM{GuOFg{KM7:TR?=NED5dW1USU6JRWK=
U-87-MGNWnB[FA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknETWM2OD1zM{OuOlA1KM7:TR?=MlTLV2FPT0WU
LB2518-MELNG\DOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33sRmlEPTB;MUO1Mlk6OyEQvF2=MUjTRW5ITVJ?
HCT-116NGS5NHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HvZmlEPTB;MUO3MlIyPyEQvF2=MmrPV2FPT0WU
Ca9-22NWHp[VROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3u0TGlEPTB;MUO5Mlg{OyEQvF2=NUHkUG5SW0GQR1XS
COR-L88NYr5c5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4j2bGlEPTB;MUSyMlE1KM7:TR?=MW\TRW5ITVJ?
CP50-MEL-BNXvZd4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHiwXnVKSzVyPUG0OE42ODFizszNMUDTRW5ITVJ?
OVCAR-8M3Hi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILJU2NKSzVyPUG0OU43OzZizszNM{PSfnNCVkeHUh?=
SK-MEL-3NX;sU|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTjc|BGUUN3ME2xOFcvQDd6IN88US=>M3XKbXNCVkeHUh?=
GT3TKBM1mySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTF2OT65Nlgh|ryPMlHHV2FPT0WU
KYSE-450MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjQUGdKSzVyPUG1NU42OzlizszNNVLuSVZmW0GQR1XS
CAPAN-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTF3Mz6wOlQh|ryPMVvTRW5ITVJ?
BENM3q2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUHacWNmUUN3ME2xOVMvQTJ6IN88US=>NUPt[ngyW0GQR1XS
NCI-H1304M4TMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXntfJJjUUN3ME2xOVQvPjl2IN88US=>MV;TRW5ITVJ?
KU812NFLxPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;nOWlEPTB;MUW4MlY4PCEQvF2=MoXNV2FPT0WU
Capan-2NFjq[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEL5dpRKSzVyPUG2NE42PTNizszNNGm1fI5USU6JRWK=
A673MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrjflJOUUN3ME2xOlEvPzB3IN88US=>NF;pVGdUSU6JRWK=
SASMl62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTF4Mj62O|gh|ryPNGT6T|hUSU6JRWK=
NYNVHTZ3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET5e5dKSzVyPUG2OU4{OTRizszNNEjDe5ZUSU6JRWK=
HCE-4NUnaOm57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnxTWM2OD1zNk[uPFQ2KM7:TR?=NGq5d2tUSU6JRWK=
MDA-MB-231NG\yWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3HZ|ZwUUN3ME2xO|cvPTB|IN88US=>NInicI5USU6JRWK=
no-10MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXlcXA2UUN3ME2xO|gvOTN2IN88US=>MmnsV2FPT0WU
MZ7-melNFHzPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1m2W2lEPTB;MUe4MlQ3PyEQvF2=NHHsbnZUSU6JRWK=
NCI-H82M1rlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXJTWM2OD1zOECuNVY2KM7:TR?=MXHTRW5ITVJ?
CAL-72NHvn[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjnblRKSzVyPUG4OU4xPTRizszNMomzV2FPT0WU
NCI-SNU-5M3jSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfWdnhrUUN3ME2xPFYvQDRizszNNEDDfFhUSU6JRWK=
OVCAR-4MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVnLSHBRUUN3ME2xPFgvOzN|IN88US=>NVjycnRQW0GQR1XS
SCC-9MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m0cGlEPTB;MUmxJO69VQ>?MlH6V2FPT0WU
KYSE-150Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTF7MT64PFgh|ryPNVLoTVdLW0GQR1XS
HT-29MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXraW4hkUUN3ME2yNFEvOjF{IN88US=>NWPU[|lnW0GQR1XS
COLO-678MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULkTmVjUUN3ME2yNFEvPDVizszNM{TWc3NCVkeHUh?=
NCI-H650MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmr1TWM2OD1{MEKuNVA{KM7:TR?=MkXFV2FPT0WU
HuCCT1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTJyND6yNFgh|ryPNH6zSlNUSU6JRWK=
SW1116MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmDOTWM2OD1{MEeuNFc4KM7:TR?=M3HC[XNCVkeHUh?=
DBTRG-05MGNHTYZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV[0e3BDUUN3ME2yNFcvQTB7IN88US=>NEn4SXRUSU6JRWK=
SW982MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\we2lEPTB;MkC3Mlk1QCEQvF2=MV7TRW5ITVJ?
RCM-1M3rw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHrTWM2OD1{MUSuO|YzKM7:TR?=MWDTRW5ITVJ?
COLO-320-HSRMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTTTWM2OD1{MU[uNVI2KM7:TR?=NGe4dYxUSU6JRWK=
KNS-42NEH1epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;qTWM2OD1{MU[uOVc1KM7:TR?=M2K1OnNCVkeHUh?=
C2BBe1M2eyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETxVY1KSzVyPUKzNU46ODVizszNNXvCT4liW0GQR1XS
CCRF-CEMM2TVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\4TWM2OD1{NEOuO|k2KM7:TR?=MmS5V2FPT0WU
SH-4MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPxc3ZKSzVyPUK0Ok4xQSEQvF2=NY\XbY1sW0GQR1XS
LS-1034Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXmwOoxDUUN3ME2yOFYvOjZ4IN88US=>M1HJcHNCVkeHUh?=
NCI-H2347MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PyfmlEPTB;MkS3MlcyOyEQvF2=NHqycVdUSU6JRWK=
RPMI-8866MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXRTWM2OD1{NEmuNlch|ryPM4XLcXNCVkeHUh?=
GAKMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFq5T3NKSzVyPUK1N{4xODJizszNMknPV2FPT0WU
NB6NWXuS5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XpfmlEPTB;MkewMlEh|ryPNXnHZ3hNW0GQR1XS
COLO-680NM3;OUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPQ[ms6UUN3ME2yO|IvPTJ5IN88US=>NWnISXZrW0GQR1XS
RERF-LC-MSM{i0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLxTWM2OD1{N{[uNFA4KM7:TR?=MoHXV2FPT0WU
TGBC11TKBMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTiTWM2OD1{N{iuNVc5KM7:TR?=MWHTRW5ITVJ?
C8166NVjqT4xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXTZXlKSzVyPUK3PE42ODZizszNM4HQT3NCVkeHUh?=
HDLM-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fidWlEPTB;Mkm0MlQxQSEQvF2=M3z3WHNCVkeHUh?=
IGR-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTqWmhKSzVyPUK5OU43PTlizszNNE\tO|RUSU6JRWK=
FADUM17ZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlj0TWM2OD1{OUeuOVEh|ryPNWDxco1vW0GQR1XS
L-428NYexSHVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJ7Nz62NVYh|ryPM3PNTXNCVkeHUh?=
LU-65M1zTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTNyND6zNkDPxE1?NH3wV3BUSU6JRWK=
HELMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTjTWM2OD1|MEmuPVg{KM7:TR?=MofzV2FPT0WU
NCI-H810NX7ZNHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1m5c2lEPTB;M{GwMlU4KM7:TR?=NYnFWGNFW0GQR1XS
C3AM{\UeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHjTWM2OD1|MUGuPFAzKM7:TR?=NYW1cXREW0GQR1XS
NCI-H630M1i2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorzTWM2OD1|M{KuNlk1KM7:TR?=NFOxZppUSU6JRWK=
KP-N-YNMkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnLZo5VUUN3ME2zOFEvOTJ|IN88US=>Ml3CV2FPT0WU
MOLT-13M12weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vTWGlEPTB;M{SyMlMzPiEQvF2=MXfTRW5ITVJ?
NCI-H1993NHH5UWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Tpe2lEPTB;M{SyMlM3PSEQvF2=MX3TRW5ITVJ?
BE-13MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDmU2hKSzVyPUO0OE4yPjdizszNMmDJV2FPT0WU
IST-SL1NWrV[Jk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3PdmdKUUN3ME2zOFcvPDBzIN88US=>NHzTeIlUSU6JRWK=
TE-9NXnIcFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTN4Mz61PFkh|ryPMWrTRW5ITVJ?
LU-135NEXROGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3v0OGlEPTB;M{[3MlA{PSEQvF2=NV3ye4FKW0GQR1XS
T84MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPtTWM2OD1|N{SuO|EzKM7:TR?=NYrPOGNlW0GQR1XS
K-562NFzDSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXkd5BKSzVyPUO4N{4{PiEQvF2=NEPJdohUSU6JRWK=
SBC-5NH[yN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XDd2lEPTB;M{i2Mlk5PSEQvF2=NXrnV3R[W0GQR1XS
NB17NG\TSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rTSGlEPTB;M{myMlU6PiEQvF2=M1P5PXNCVkeHUh?=
NCI-H2052NEH6dppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTN7OD60O|Ih|ryPMlTDV2FPT0WU
HCC38NImweXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDNWXE4UUN3ME20NFEvPTl|IN88US=>M4HvbHNCVkeHUh?=
NCI-H69NFfGU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTR2MT6wPFMh|ryPMXrTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.

Protocol(Only for Reference)

Kinase Assay: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

Cell Assay: [2]

Cell lines A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
Concentrations 0, 0.3, 1 and 3 μM
Incubation Time 72 or 96 hours
Method MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

Animal Study: [2]

Animal Models SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
Formulation Formulated in 30% Captisol
Dosages 120 mg/kg
Administration Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Yan L, AACR Annual Meeting 2009: Abstract Number: DDT01-1.

[2] Hirai H, et al. Mol Cancer Therapy, 2010, 9(7), 1956-1967.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent  ...more Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|St  ...more Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adu  ...more Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|  ...more Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

view more

Chemical Information

Download MK-2206 2HCl SDF
Molecular Weight (MW) 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

Customer Product Validation(18)


Click to enlarge
Rating
Source Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines Ser78 cells
Concentrations 5 µM
Incubation Time 1 h
Results Two selective AKT inhibitors MK-2206 and GDC-0068, both significantly reduced MKK4 phosphorylation on Ser78 in axons after injury.

Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck
Method 3D migration model
Cell Lines WT or Rap1b-/- neutrophil
Concentrations 2 uM
Incubation Time
Results MK-2206 treatment completely reversed elevated TEM across mouse endothelial cells of Rap1b-/- neutrophils to WT levels (A). It reduced ECM degradation of Rap1b -/- neutrophils, and inhibited their multiple protrusions (B and C). Furthermore, almost all Rap1b -/- cells treated with MK-2206 were found at the endothelial cell junctions (D).

Click to enlarge
Rating
Source Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines HUVECs
Concentrations 1 uM
Incubation Time 8 h
Results Because YAP is also a known substrate of Akt21, we examined whether blockade of the Akt pathway affects YAP phosphorylation. Both Ly294002, an inhibitor of phosphoinositide 3-kinase (PI3K), and MK-2206, an allosteric inhibitor of Akt, suppressed cell contact-mediated YAP phosphorylation.

Click to enlarge
Rating
Source Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck
Method Immunoblotting
Cell Lines CXCR4S338X-expressing BCWM.1 cells
Concentrations 0.5 uM
Incubation Time 6 h
Results As AKT and ERK, but not BTK, show continued SDF-1a-triggered activation in CXCR4S338X-expressing WM cells treated with ibrutinib, we next sought to clarify if AKT and ERK contributed to the enhanced survival of these cells. It therefore treated SDF-1acultured CXCR4S338X BCWM.1 cells with either AKT- (MK-2206 and AZD-5363) or MEK- (AS-703026, AZD-6244 and UO126) specific inhibitors with and without ibrutinib (0.5 uM) for 6 h so as to clarify the contribution of AKT and ERK to ibrutinib resistance. The inhibitory activity of MK-2206, as well as AS-703026, AZD-6244 and UO126 was confirmed by western blot analysis for pAKT (S473) and pERK (T202/Y204), respectively.

Click to enlarge
Rating
Source Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Recently Viewed Items

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us